LHX3 Gene Pituitary Hormone Deficiency Combined Type 3 Genetic Test

Introduction

The LHX3 gene is responsible for producing a protein that plays a crucial role in the development and function of the pituitary gland. Mutations in this gene can lead to a condition called pituitary hormone deficiency, combined type 3 (CPHD3).

Symptoms and Diagnosis

CPHD3 is a rare genetic disorder characterized by a deficiency in multiple pituitary hormones, including growth hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and others. This can result in various symptoms depending on the specific hormones affected, such as short stature, delayed puberty, fatigue, weight gain, and low blood sugar.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of an individual’s genes. It can detect mutations or variations in the LHX3 gene that may be responsible for CPHD3. This type of testing allows for a comprehensive analysis of multiple genes simultaneously, providing a more accurate and efficient diagnosis compared to traditional sequencing methods.

Test Details

The LHX3 Gene Pituitary Hormone Deficiency Combined Type 3 Genetic Test is available at DNA Labs UAE. The test components include:

• Test Name: LHX3 Gene Pituitary Hormone Deficiency Combined Type 3 Genetic Test
• Price: 4400.0 AED
• Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
• Report Delivery: 3 to 4 Weeks
• Method: NGS Technology
• Test Type: Hepatology Nephrology Endocrinology Disorders
• Doctor: General Physician
• Test Department: Genetics

Pre Test Information

Prior to undergoing the LHX3 Gene Pituitary Hormone Deficiency Combined Type 3 Genetic Test, it is important to provide the clinical history of the patient who is going for the test. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with LHX3 Gene Pituitary Hormone Deficiency, combined type 3 NGS Genetic DNA Test gene LHX3.

Benefits of Genetic Testing

By identifying the specific mutation in the LHX3 gene, NGS genetic testing can help confirm a diagnosis of CPHD3 and provide valuable information for genetic counseling, treatment planning, and management of the condition. It can also be useful for identifying carriers of the mutation within families and facilitating early intervention and monitoring for affected individuals.

Genetic testing plays a crucial role in understanding and managing genetic disorders, allowing for personalized treatment plans and improved patient outcomes.